Autres langues Cue Biopharma, Inc.

Actions

CUE

US22978P1066

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
1,42 ^USD	+4,03 %		-5,33 %	-46,21 %

08/04	Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
28/03	Cue Biopharma, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights	08/04
North American Morning Briefing : Inflation Data, -2-	08/04
Cue Biopharma to Host Business Update Call and Webcast	02/04
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
North American Morning Briefing : Tech in Focus on -2-	25/03
North American Morning Briefing : Investors -2-	18/03
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium	29/02
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	23/11
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit	22/11
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights	09/11
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	07/11
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	07/11
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
Cue Biopharma Reports Prolonged Survival in Phase 1 Trials of CUE-101; Shares Climb	03/11
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023	03/11
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023	03/11
Cue Biopharma to Host Business Update Call and Webcast	02/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cue Biopharma, Inc.

Actions

CUE

US22978P1066

Autres langues

Filtres